Armen Shanafelt serves as Executive at Aeglea BioTherapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Armen Shanafelt has executed 12 insider transactions totaling $15.3M, demonstrating a bullish approach to their equity position. Their most recent transaction on Dec 13, 2021 involved purchasing 14,685 shares valued at $53.6K.
Armen Shanafelt currently holds 150,000 shares of Aeglea BioTherapeutics, Inc. (AGLE), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Armen Shanafelt has been a net buyer of AGLE stock. They have purchased $15.3M and sold $0 worth of shares.
Armen Shanafelt's most recent insider trade was on Dec 13, 2021, when they purchased 14,685 shares at $3.65 per share.
Get notified when new Form 4 filings are submitted
| $3.65 |
| Discretionary |
| Dec 9, 2021 | AGLE | $447.0K | Purchase | 121,799 | $3.67 | Discretionary |
| Apr 23, 2018 | SURF | $0 | Conversion | 3,181,817 | $N/A | Discretionary |
| Apr 23, 2018 | SURF | $4.0M | Purchase | 266,000 | $15.00 | Discretionary |
| Jul 5, 2017 | ALRN | $3.8M | Purchase | 250,000 | $15.00 | Discretionary |
| Jul 5, 2017 | ALRN | $0 | Conversion | 844,987 | $N/A | Discretionary |
| Aug 16, 2016 | PTGX | $0 | Conversion | 630,541 | $N/A | Discretionary |
| Aug 16, 2016 | PTGX | $0 | Conversion | 678,712 | $N/A | Discretionary |
| Aug 16, 2016 | PTGX | $7.0M | Purchase | 583,333 | $12.00 | Discretionary |
| Aug 16, 2016 | PTGX | $0 | Conversion | 206,896 | $N/A | Discretionary |
| Apr 12, 2016 | AGLE | $0 | Conversion | 2,010,924 | $N/A | Discretionary |